Bright Peak’s team works with a passion for innovation and bold science. We are an international research-driven organization dedicated to discovering and developing cutting edge therapies that will make a difference in the lives of patients. We aim to create a vibrant and international corporate culture and are currently hiring in our Basel, Switzerland and Southern California locations.">
Bright Peak Therapeutics
Edit

Bright Peak Therapeutics

https://brightpeaktx.com/
Last activity: 21.10.2024
Active
Categories: ChemicalCorporateCultureDevelopmentEngineeringScienceTechnology
Bright Peak are developing a portfolio of first-in-class and best-in-class cytokines with optimized biological properties for the treatment of cancer and autoimmune diseases. Through a variety of proprietary technology platforms, Bright Peak is uniquely abled to conjugate its cytokines as payloads to antibodies, creating bespoke, novel and proprietary “Bright Peak Immunocytokines”, and to other cytokines as “duokines”.
The Bright Peak Immunocytokines allow tissue- and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy. One of the many advantages of our approach is its "off-the-shelf" feature. Using a pioneering site-specific ADC-like chemical conjugation technology, any therapeutic antibody at any stage of development can be conjugated with Bright Peak’s cytokine payloads of choice, eliminating the current complexities of antibody engineering and cell line development.

Bright Peak’s team works with a passion for innovation and bold science. We are an international research-driven organization dedicated to discovering and developing cutting edge therapies that will make a difference in the lives of patients. We aim to create a vibrant and international corporate culture and are currently hiring in our Basel, Switzerland and Southern California locations.
Followers
1.62K
Website visits
3.4K /mo.
Mentions
9
Location: Switzerland, Basel-City, Basel
Employees: 51-200
Total raised: $197M
Founded date: 2017

Investors 1

DateNameWebsite
-RA Capital...racap.com

Funding Rounds 2

DateSeriesAmountInvestors
17.06.2024Series C$90M-
10.06.2021Series B$107MRA Capital...

Mentions in press and media 9

DateTitleDescription
21.10.2024Bright Peak Therapeutics enters the clinic with first immunotherapy for cancer Using innovative protein engineering and a proprietary chemical protein synthesis and conjugation platform, Bright Peak is developing a pipeline of first-in-class multifunctional molecules. The company’s lead program, BPT567, is designed t...
17.06.2024Bright Peak Therapeutics raises USD90 million to advance lead program into clinical trials Bright Peak Therapeutics is a biotechnology company advancing a portfolio of multifunctional immunotherapies to treat cancer and other diseases. “We are now well positioned to bring much needed innovation to the field of anti-PD-1 immune-c...
15.06.2024Bright Peak Therapeutics Secures $90 Million to Revolutionize Cancer TreatmentBright Peak Therapeutics, a biotech startup specializing in cutting-edge immunotherapies, has secured a whopping $90 million in Series C funding. This significant investment will propel the development of their groundbreaking PD1-IL18 immun...
14.06.2024Bright Peak Therapeutics secures USD 90 million in Series C funding to propel innovative immunotherapy forwardBright Peak Therapeutics secures USD 90 million in Series C funding to propel innovative immunotherapy forward 14.06.2024 17:31, Rita Longobardi linkedIn facebook twitter instagram youtube --> The Biotech startup Bright Peak Therapeutics...
11.06.2024Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials-- Lead Program, BPT567, will be the first PD1-IL18 immunoconjugate to enter the clinic; Phase 1/2a study in solid tumors expected to begin in 2H 2024 – -- Financing led by Johnson & Johnson with participation by new and existing invest...
21.03.2022Seasoned Board Members for Swiss Startups
14.06.2021Bright Peak Therapeutics Closes $107 Million Financing Round
10.06.2021Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors--Proceeds to advance company’s pipeline of next-generation cytokine immunotherapies-- --Laura Shawver, Christine Siu join as independent directors-- BASEL, Switzerland and SAN DIEGO, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Bright Peak Th...
-Bright Peak Therapeutics“Home - Bright Peak Therapeutics”

Reviews 0

Sign up to leave a review

Sign up Log In